Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Maravai LifeSciences Q1 2026 Earnings Call - EBITDA Guidance Raised Sharply on Margin Expansion and Strong Base Demand
Maravai LifeSciences delivered a robust Q1 2026, posting $65.8 million in revenue, up 41% year-over-year, with base business growth of 10% after excluding non-recurring COVID CleanCap revenue. The qua...
- Total Q1 revenue reached $65.8 million, representing 41% year-over-year growth, with base business growth of 10% after excluding non-recurring COVID CleanCap revenue.
- Adjusted EBITDA surged to $20.3 million, exceeding expectations and improving over $30 million year-over-year, driven by favorable product mix and cost discipline.
- Management substantially raised full-year adjusted EBITDA guidance to $30–32 million, up $61–63 million year-over-year, reflecting improved profitability flow-through.
- +12 more takeaways
PRA Group Q1 2026 Earnings Call - Legal & Digital Channels Drive 11% Cash Collection Growth
PRA Group delivered a solid start to 2026 with cash collections up 11% year-over-year, fueled by accelerating legal and digital channels in the U.S. and broad-based strength in Europe. The company mai...
- Cash collections grew 11% year-over-year to $552 million, with U.S. collections up 11% and Europe up 15%, exceeding guidance by 3% globally.
- Legal channel expansion drove U.S. growth, with legal collections rising 27% to $141 million and now representing 53% of U.S. core cash collections, up from 46% in Q1 2025.
- Adjusted EBITDA for the trailing twelve months rose 14% to $1.3 billion, outpacing cash collection growth and highlighting improving operating leverage despite a $15 million increase in legal collection costs.
- +7 more takeaways
PubMatic Q1 2026 Earnings Call - Agentic AI Drives 80% Emerging Revenue Growth
PubMatic reported a strong Q1 2026 with revenue of $62.6M and adjusted EBITDA of $2.6M, beating guidance. The company highlighted 13% underlying YoY growth and an 80% surge in emerging revenues, now r...
- Revenue reached $62.6 million and adjusted EBITDA was $2.6 million, both beating preliminary guidance and the high end of the guidance range.
- Underlying business grew 13% year-over-year, representing 83% of total revenue, excluding the legacy DSP that was divested mid-2025.
- Emerging revenues surged over 80% year-over-year, now accounting for 14% of total revenue, driven primarily by the adoption of AgenticOS and AI-powered tools.
- +7 more takeaways
Mitek (MITK) Q2 FY2026 Earnings Call - Record Revenue and Profitability Drive Raised Full-Year Outlook
Mitek delivered a record fiscal second quarter, with revenue rising 6% to $54.8 million and adjusted EBITDA hitting an all-time high of $22.3 million. The company raised its full-year revenue guidance...
- Record Q2 revenue of $54.8 million, up 6% year-over-year, driven by strong fraud and identity demand and seasonal check verification renewals.
- Adjusted EBITDA set a company record at $22.3 million, representing a 41% margin and reflecting favorable revenue mix and operating leverage.
- Full-year revenue guidance raised to $189 million–$198 million, with the midpoint implying 8% year-over-year growth.
- +7 more takeaways
Innodata Q1 2026 Earnings Call - Record Revenue and Margin Expansion on AI Data and Agentic AI Platform Breakthroughs
Innodata delivered a record first quarter of 2026, with revenue surging 54% year-over-year to $90.1 million, adjusted EBITDA jumping 96% to $25 million, and adjusted gross margins expanding 6 percenta...
- Revenue reached a record $90.1 million, up 54% year-over-year and 24% sequentially, significantly exceeding analyst consensus by approximately $13.6 million or 18%.
- Adjusted EBITDA surged 96% year-over-year to $25 million, representing a 28% margin and beating analyst estimates by an extraordinary 139%.
- Adjusted gross margins expanded by 6 percentage points to 47%, marking a 7-point improvement over the company's previously stated 40% public target.
- +7 more takeaways
Xenon Pharmaceuticals Q1 2026 Earnings Call - Azetukalner NDA Filing on Track for Q3 2026 as $750M Financing Secures Runway to 2029
Xenon Pharmaceuticals reported strong operational progress in Q1 2026, anchored by positive Phase III X-TOLE2 data for azetukalner (AZK) in focal onset seizures, which exceeded expectations and demons...
- Xenon Pharmaceuticals completed a $747.5 million public offering in Q1 2026, raising cash to $1.3 billion and extending its operating runway into 2029, providing ample capital for the AZK launch and pipeline advancement.
- The Phase III X-TOLE2 study for azetukalner (AZK) in focal onset seizures met its primary endpoint with a 53.2% reduction in monthly seizure frequency at 25 mg, exceeding Phase II-B results and demonstrating rapid onset of action without titration.
- Xenon targets an NDA submission to the FDA in Q3 2026, with a base-case expectation of approval in late 2027 or early 2028, assuming a standard 12-month review and 3-month DEA scheduling period.
- +7 more takeaways
Comstock Inc. Q1 2026 Earnings Call - Transition from Balance Sheet Repair to Operational Execution at Scale
Comstock Inc. is shifting from a phase of balance sheet recapitalization to operational execution, marking a pivotal moment for the company. The first quarter of 2026 saw the completion of a $57.5 mil...
- Comstock completed a $57.5 million oversubscribed equity financing, leaving a cash balance of over $53 million and eliminating all legacy debt, significantly strengthening its balance sheet.
- The company is transitioning from balance sheet repair to operational execution, with its first solar panel recycling facility in Silver Springs, Nevada, nearing completion and scheduled for commercial operations in June.
- Comstock plans to monetize all remaining mining assets, with a definitive agreement expected in Q3 2026, which will simplify the company, reduce annual cash spending by up to $1.5 million, and provide cash for redeployment.
- +7 more takeaways
Natera Q1 2026 Earnings Call - Record MRD Volumes and Japan Launch Drive Revenue Reset
Natera reported a record Q1 2026 with revenues of $697 million, reflecting 39% year-over-year growth and a milestone of over 1 million units processed in a single quarter. The company's clinical MRD b...
- 1. Natera reported Q1 2026 revenues of $697 million, a 39% year-over-year increase, marking a significant acceleration in growth at scale.
- 2. The company processed over 1 million units in a single quarter for the first time, with Signatera clinical MRD volume hitting a record 249,000 tests, up 55% year-over-year.
- 3. Management reset the full-year revenue guidance upward by $120 million at the midpoint, reflecting strong volume momentum and realized ASP growth.
- +12 more takeaways
Crinetics Pharmaceuticals Q1 2026 Earnings Call - PALSONIFY Launch Momentum Accelerates With 232 New Patient Enrollments
Crinetics Pharmaceuticals delivered a strong first quarter 2026, driven by the accelerating launch of PALSONIFY for acromegaly. The company enrolled 232 new patients, generated $10.3 million in net pr...
- PALSONIFY generated $10.3 million in net product revenue in Q1 2026, with total company revenue reaching $10.7 million including $0.4 million from a Japanese licensing deal.
- The company enrolled 232 new patients on PALSONIFY during the quarter, demonstrating consistent weekly growth and expanding beyond early adopters.
- Treatment-naive patients now account for 15% of new PALSONIFY enrollments, up from 5% in Q4 2025, signaling growing physician confidence in first-line use.
- +7 more takeaways
Myomo Q1 2026 Earnings Call - Recurring Revenue Shift Accelerates as O&P Partnerships and Payer Contracts Expand Market Access
Myomo delivered a disciplined Q1 2026 that confirmed its pivot toward recurring patient sources and stronger unit economics. Revenue rose 3% to $10.1 million, driven by a 9% increase in average sellin...
- Q1 2026 revenue reached $10.1 million, up 3% year-over-year, driven by a 9% increase in average selling price to $58,800 from Medicare fee updates and a favorable payer mix.
- Gross margin expanded 100 basis points to 68.2%, while operating expenses declined 1% to $10.1 million, resulting in a 20% improvement in adjusted EBITDA.
- Recurring patient sources now account for 49% of revenue, up from 25% in Q1 2025, signaling a successful shift away from high-cost direct-to-consumer advertising.
- +7 more takeaways